Indications for IVIG in rheumatic diseases

Research output: Contribution to journalArticlepeer-review

91 Downloads (Pure)


The use of IVIG to treat a wide variety of immune-driven diseases has grown rapidly, although the mechanism of action is not completely understood. Increasing demand for IVIG coupled with concerns regarding potential transmissible agents has led to worldwide supply shortages. National agencies have therefore produced guidelines for its use, with the latest England and Wales guideline being published in 2011. Due to the rarity of the rheumatic diseases, the evidence for IVIG use has been shown to be lacking in some areas and promising in others. Conditions in which IVIG has been shown to have benefit include ITP, Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy occurring in the context of rheumatic disease, as well as in SLE, idiopathic inflammatory myopathies and ANCA-associated vasculitides. This review looks at current IVIG use and is designed to be an aid for rheumatologists when considering the use of IVIG in clinical practice.
Original languageEnglish
Pages (from-to)383-391
Number of pages8
JournalRheumatology (Print)
Issue number3
Publication statusPublished - 2015


Dive into the research topics of 'Indications for IVIG in rheumatic diseases'. Together they form a unique fingerprint.

Cite this